Kirby McInerney LLP Announces Investigation Against Hims & Hers Health, Inc. (HIMS) on Behalf of Investors

Core Viewpoint - Hims & Hers Health, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and safety risks associated with its products [1][3]. Group 1: Investigation Details - Kirby McInerney LLP is investigating claims against Hims & Hers regarding possible violations of federal securities laws and other unlawful business practices [1]. - The investigation is prompted by allegations that Hims & Hers engaged in deceptive marketing and sold illegitimate versions of Novo Nordisk's weight loss drug Wegovy [3]. Group 2: Partnership and Market Impact - On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk to sell Wegovy [3]. - The partnership was terminated on June 23, 2025, leading to a significant decline in Hims & Hers' stock price, which fell approximately 34% from $64.22 to $41.97 per share [3].